India is the largest global supplier of generic drugs and the Indian pharmaceutical industry is growing rapidly, projected to reach $65 billion by 2024 and $130 billion by 2030. Growth is driven by increasing R&D investments, government initiatives, and rising domestic healthcare demand.
Mutual funds are important during market volatility because they offer diversification, reducing the risk of significant losses, and provide professional management to navigate fluctuating markets.
Additionally, mutual funds are cost-efficient compared to managing individual securities and follow disciplined investment approaches that help investors avoid emotional decisions during turbulent times.
Listed below are some of the Pharmaceutical stocks in which Mutual Funds have increased their holding in Q2FY25, that you can add to your watchlist
Ami Organics
AMI Organics (AMI) is one of the leading research and development-driven manufacturers of specialty chemicals, focused on the development and manufacturing of advanced pharmaceutical intermediates for regulated and generic active pharmaceutical ingredients, New Chemical Entities, and key starting materials for agrochemical and fine chemicals.
With a market capitalization of Rs. 6,356.71 Crores, the shares of Ami Organics Limited were trading at Rs. 1552.90 per equity share, up 0.69 percent from the previous day’s close price of Rs.1,542.20.
In Q2FY25 the Mutual Fund Corporations increased their holding in Ami Organics Limited from 8.61 percent in Q1FY25 to 13.07 percent in Q2FY25 by purchasing an additional 4.46 percent stake.
Its Revenue from operations grew by 14.93 percent from Rs. 154 Crores in Q1FY24 to Rs. 177 Crores in Q1FY25, accompanied by profits of Rs. 22 Crores to Rs. 15 Crores.
Eris Lifesciences
Eris Lifesciences Limited is a leading player in the domestic branded formulations market engaged in the business of manufacture and marketing of pharmaceutical products.
With a market capitalization of Rs. 17,424.26 Crores, the shares of Eris Lifesciences Limited were trading at Rs. 1,280.20 per equity share, up 0.26 percent from the previous day’s close price of Rs. 1,276.85.
In Q2FY25 the Mutual Fund Corporations increased their holding in Eris Lifesciences Limited from 14.52 percent in Q1FY25 to 17.03 percent in Q2FY25 by purchasing an additional 2.51 percent stake.
Its Revenue from operations grew by 55.55 percent from Rs. 460.03 Crores in Q1FY24 to Rs. 715.59 Crores in Q1FY25, accompanied by profits of Rs. 93.65 Crores to Rs. 89.42 Crores.
Gland Pharma
Gland Pharma Limited is engaged in the business of pharmaceutical research, development, manufacturing, and marketing of complex injectables with a strong presence in injectables, oncology, and ophthalmology segments.
With a market capitalization of Rs.26,575.28 Crores, the shares of Gland Pharma Limited were trading at Rs. 1,612.20 per equity share, up 0.30 percent from the previous day’s close price of Rs. 1,607.35.
In Q2FY25 the Mutual Fund Corporations increased their holding in Gland Pharma Limited from 30.53 percent in Q1FY25 to 32.83 percent in Q2FY25 by purchasing an additional 2.3 percent stake.
Its Revenue from operations grew by 15.97 percent from Rs. 1,209 Crores in Q1FY24 to Rs. 1,402 Crores in Q1FY25, accompanied by profits of Rs. 194 Crores to Rs. 144 Crores.
Pfize
With a market capitalization of Rs. 24,992.21 Crores, the shares of Pfizer Limited were trading at Rs. 5,471.80 per equity share, down 0.54 percent from the previous day’s close price of Rs. 5,501.50.
In Q2FY25 the Mutual Fund Corporations increased their holding in Pfizer Limited from 8.32 percent in Q1FY25 to 10.43 percent in Q2FY25 by purchasing an additional 2.11 percent stake.
Its Revenue from operations grew by 5.93 percent from Rs. 531 Crores in Q1FY24 to Rs. 563 Crores in Q1FY25, accompanied by profits of Rs. 94 Crores to Rs. 151 Crores.
Glenmark Lifesciences
With a market capitalization of Rs. 13,176.12 Crores, the shares of Glenmark Lifesciences Limited were trading at Rs. 1,075.40 per equity share, down 0.07 percent from the previous day’s close price of Rs. 1,076.20.
In Q2FY25 the Mutual Fund Corporations increased their holding in Glenmark Lifesciences Limited from 1.01 percent in Q1FY25 to 2.82 percent in Q2FY25 by purchasing an additional 1.81 percent stake.
Its Revenue from operations grew by 1.76 percent from Rs. 578.45 Crores in Q1FY24 to Rs. 588.62 Crores in Q1FY25, accompanied by profits of Rs. 135.45 Crores to Rs. 111.48Crores.
Written by: Bharath K.S
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
